[go: up one dir, main page]

WO1998058655A1 - Utilisation medicale d'une substance contenant de l'acide humique - Google Patents

Utilisation medicale d'une substance contenant de l'acide humique Download PDF

Info

Publication number
WO1998058655A1
WO1998058655A1 PCT/HU1998/000059 HU9800059W WO9858655A1 WO 1998058655 A1 WO1998058655 A1 WO 1998058655A1 HU 9800059 W HU9800059 W HU 9800059W WO 9858655 A1 WO9858655 A1 WO 9858655A1
Authority
WO
WIPO (PCT)
Prior art keywords
peat
humic acid
containing substance
origin
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU1998/000059
Other languages
English (en)
Inventor
Ferenc BÁNKUTI
Annamária BELEZNAY
Mária VÉGH
Lóránd Debreczeni
István GÖMÖRY
Pál GÖMÖRY
András GELLEY
Ferenc KO^'HEGYI
Imre Kiss
András KOLETÁR
Ágota LÉNÁRT
Albert MOLNÁR
Miklós MOLNÁR
György NÉMETH
Máté PETREKANITS
Zsuzsanna RÉTEI
Júlia SZÁMADÓ
János SZÖLLO^'SY
György SZABÓ
Iván SZMODIS
Zsófia MEDZIHRADSZKY
János HIDEG
András GACHÁLYI
József NAMÉNYI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Horizon-Multiplan Kutatasi Es Fejlesztesi Reszvenytarsasag
Original Assignee
Horizon-Multiplan Kutatasi Es Fejlesztesi Reszvenytarsasag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon-Multiplan Kutatasi Es Fejlesztesi Reszvenytarsasag filed Critical Horizon-Multiplan Kutatasi Es Fejlesztesi Reszvenytarsasag
Priority to AU82362/98A priority Critical patent/AU8236298A/en
Publication of WO1998058655A1 publication Critical patent/WO1998058655A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/10—Peat; Amber; Turf; Humus

Definitions

  • the invention relates to the use of a humic acid-containing substance in medicine, to pharmaceutical compositions containing as an active ingredient such a substance, and to a process for preparing this substance.
  • the pharmaceutical compositions are useful as a prophylactic to injuries of the haemopoietic system or for regeneration of the injured haemopoietic system.
  • humic acids are heteropolycondensates of widely various compositions, respectively, allomelanins, which can be found, e.g. in soils, carbon sorts and peat. Humic acids are formed through a slow decomposition process, respectively chemical and biological transformation of plant materials.
  • W. Flaig "The chemistry of humic substances", FAO/IAEA Tech. Meet. Brunswick- V ⁇ lkenrode, p. 103 to 127 (1963); . V. Cheshire et al.: “Humic Acids II. Structure of humic acids", Tetrahedron, 23, 1669-1682 (1967); M. Schnitzer and S. U.
  • humic acids contain complex, polymerized macromolecules of phenolic structure; their composition depends strongly on the site and age of their formation.
  • the metal ion- binding, particularly iron-binding, and chelate-forming properties of humic acids are well known.
  • the main peat-forming plants of the starting material referred to above are 20 to 40% of great bulrush (Schoenoplectus lacustris) and 60 to 80% of winter-sedge (Cladium mariscus).
  • the biological effects of these humic acid-containing substances were studied in several series of experiments. It surprisingly has been found that the humic acid-containing substances prepared by the process to be described later favourably influence the regeneration of the haemopoietic system injured by external whole body 60 Co gamma irradiation of the experimental animals.
  • mice Female Wistar rats of 190 to 220 g body-weight (Laboratory Animals Institute, G ⁇ d ⁇ ll ⁇ , Hungary), randomized according to weight, were used in test groups. The animals were kept in plastic cages (5 animals in each cage) at a controlled temperature of 23 ⁇ 3 °C and relative humidity of 60 ⁇ 10% under alternating illumination (12-hour cycles of light/darkness). The rats received standard diet (Code: 624, Altromin GmbH, D-32791 Heil/Lippe, Germany) and water ad libitum. The average daily food consumption was 20 g per animal.
  • the rats were acclimated to the experimental conditions for two weeks. During the experiment, the general physical condition of the animals was controlled daily. II. Test material
  • the preparations were administered to the experimental animals in various doses through a gastric tube.
  • Natural humic acid product for feeding (in the following text: HA) was prepared by grinding the normal standard rat pellet (see earlier) mixed with the required amount of the material as prepared according to the following Example 1. The mixture was homogenized, regranulated and dried at room temperature.
  • Gray Gray
  • LD50/30 value characteristic of the rat strain was found to be 7.5 Gy.
  • the haematological parameters including white blood cell (WBC) count, red blood cell (RBC) count, haemoglobin (HGB), haematocrit (HTC), platelet (PLT) count, and reticulocyte (RET) count, were determined by using MEDICOR PHA-1 and PHA-2 type haematologic automatic devices (MEDICOR Ltd., Budapest, Hungary).
  • Group 1 Whole body irradiated with 7 Gy of 60 Co gamma (standard feed + tap water).
  • Group 2 Pretreatment with HA for 7 days (240 mg/animal/day), then whole body exposure to 7 Gy and additional 4-week treatment with a dose of 240 mg/animal/day of HA.
  • Group 3 Whole-body exposure to 7 Gy, then a single treatment with a dose of 240 mg/animal/day of HA.
  • Group 4 Pretreatment with HA for 7 days (90 mg/animal/day) then whole- body exposure to 7 Gy and additional 4-week treatment with a dose of 90 mg/animal/day of HA.
  • Group 5 Whole-body exposure to 7 Gy, then a single treatment with a dose of 90 mg/animal/day of HA.
  • the experimental data were analyzed by using the Student's T test.
  • test material applied exerts its effect in several therapeutical doses in the case of a high-dose 60 Co gamma whole-body exposure in the normalization of the irradiation- induced injuries of the haemopoietic system.
  • the action becomes most favourable by also using the test material before irradiation as a pretreatment.
  • humic acid- containing compositions according to the invention can be used advantageously to prevent injuries to the haemopoietic system of various origins or for an effective, increased regeneration of the injured haemopoietic system.
  • compositions according to the present invention can be effectively used in human therapy in cases in which the human body is affected by an ionizing radiation during therapy or because of other events (reactor accident, accidental radiation effect affecting the patient or the handling crew, etc.). Additional experiments indicate that the compositions according to the present invention can also be utilized to increase the regeneration of the haemopoietic system when it is injured during chemotherapy treatments.
  • the invention relates to a pharmaceutical composition useful for the prevention of injuries of the haemopoietic system and for regeneration of an injured haemopoietic system, in which the composition comprises an effective amount, suitably 0.01 to 99.9% by weight, of humic acid-containing substance of peat origin together with the usual additives.
  • the compositions contain 1.0 to 25.0% by weight of humic acid-containing substance of fen peat origin and 75 to 99% by weight of known, therapeutical ly acceptable additive(s) in solid, liquid, or gel form.
  • the invention further relates to a process for the preparation of a humic acid-containing substance.
  • This process is characterized in that, as a starting material, juvenile peat of fen origin of not more than 15,000 years of age is used, which had been formed from at least 20% of great bulrush (Schoenoplectus lacustris) and at least 40% of winter-sedge (Cladium mariscus) as peat-forming plants.
  • the peat is stirred with an aqueous alkaline solution of pH 7.5 to 10.5 to obtain a suspension.
  • at least a 2.5-fold amount of an alkaline solution is used to form the suspension.
  • An aqueous solution of alkaline metal hydroxides preferably sodium or potassium hydroxide, and/or a basic aqueous solution of alkaline salts, like sodium carbonate, trisodium phosphate, or potassium pyrophosphate, may be used as the aqueous alkaline solution.
  • the upper phase obtained after settling of the mixture is suitably adjusted to 10 to 100 g/L of humic acid content, or concentrated by dehydration, or brought into solid form. Evaporation under reduced pressure, drying with atomization, lyophilization, and other or similar technical procedures may be applied.
  • the appropriately selected peat is homogenized by drying, crushing, and grinding; the peat grist containing humic acid is suspended in a mildly alkaline, i.e. pH 7.5 to 10.5, aqueous medium, and settled; after separation from the lower phase, the pH value of the supernatant is, if desired, adjusted to pH 5 to 7, and then, if desired, the mixture is concentrated or dried by dehydration.
  • a mildly alkaline i.e. pH 7.5 to 10.5, aqueous medium, and settled
  • the pH value of the supernatant is, if desired, adjusted to pH 5 to 7, and then, if desired, the mixture is concentrated or dried by dehydration.
  • the appropriately selected dried and homogenized peat is treated with a dilute, e.g. at most 5% by weight, alkaline solution of pH 7.5 to 10.5; then, the dry substance content of the recovered suspension is determined, and the humic acid-containing substance is transformed into the desired form, e.g. suspended or powdered.
  • a dilute e.g. at most 5% by weight, alkaline solution of pH 7.5 to 10.5; then, the dry substance content of the recovered suspension is determined, and the humic acid-containing substance is transformed into the desired form, e.g. suspended or powdered.
  • the advantages of the invention can be summarized as follows: 1 )
  • the pharmaceutical compositions according to the present invention act within a novel and highly significant field by curing diseases related to injuries of the haemopoietic system; and 2)
  • the invention provides a well-reproducible process for the preparation of the pharmaceutical compositions by ensuring a humic acid-containing substance of stable composition.
  • Peat of 3,000 to 7,000 years of age originating from a depth of 0.5 to 2.5 m was used as the starting material, containing 20 to 40% of great bulrush and 60 to 80% of winter-sedge as peat-forming plants.
  • the peat was treated with a 1 % potassium pyrophosphate (K4P2O7) solution at 45°C in an acid-resistant or enamel-lined vessel, fitted with a heater and a stirrer, under constant stirring. After dissolving 1 part by weight of potassium pyrophosphate in 100 parts by weight of tap water heated to a maximum of 45°C, 50 parts by weight of peat having a maximum moisture content of 30% were added. The suspension obtained contained about 10% of peat material. The recovery lasted not more than 48 hours. Within this period, after stirring for 1 hour, the mixture was subjected to vigorous, particle-grinding stirring for an additional 2 hours in a Dispax reactor (IKA Werke, Germany) for achieving a homogeneous particle distribution.
  • K4P2O7 potassium pyrophosphate
  • the humic acid-containing liquid removed from the settling tank by suction was stirred in the dilution tank for at least 30 minutes.
  • 30 ml of homogeneous humic acid- containing suspension were dried to constant weight at 130°C in a drying oven.
  • Example 3 After adding 1400 g of maize starch and 70 g of poly vinyl pyrrolidone to 1 L of a suspension according to Example 1 , containing 30 g/L of humic acid, a granulation mixture was prepared, granulated through a screen of 1.2 mm, dried at room temperature, i.e. maximum at 25°C, and re- granulated to give grayish loose granules.
  • humic acid granules from a concentrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention, qui concerne l'utilisation médicale d'une substance contenant de l'acide humique, concerne également, non seulement des compositions pharmaceutiques contenant cette substance comme principe actif, mais aussi un procédé permettant de préparer cette substance. Cette substance contenant de l'acide humique s'utilise de préférence sous la forme d'une composition pharmaceutique constituée pour 0,01 à 99,90 % de sa masse d'une telle substance contenant de l'acide humique provenant de la tourbe, laquelle substance est associée à des excipients et/ou tous autres additifs connus. L'invention concerne également un procédé de préparation d'une substance contenant de l'acide humique et provenant de la tourbe. Ce procédé consiste à prendre comme matière première de la tourbe jeune, ne faisant pas plus de 10.000 ans, issue de scirpe des étangs ou de la laîche d'hiver. Le procédé consiste ensuite à préparer une suspension en agitant la tourbe dans une solution aqueuse alcaline (pH 7,5 à 10,5), puis à utiliser la phase supérieure de la suspension ainsi obtenue en amenant sa teneur en acide humique à 10-100 g/l. Le procédé consiste enfin à concentrer cette phase ou à en obtenir la phase solide par déshydratation.
PCT/HU1998/000059 1997-06-24 1998-06-23 Utilisation medicale d'une substance contenant de l'acide humique Ceased WO1998058655A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU82362/98A AU8236298A (en) 1997-06-24 1998-06-23 Use of a humic acid-containing substance in medicine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701093A HUP9701093A1 (hu) 1997-06-24 1997-06-24 Huminsavtartalmú gyógyászati készítmény
HUP9701093 1997-06-24

Publications (1)

Publication Number Publication Date
WO1998058655A1 true WO1998058655A1 (fr) 1998-12-30

Family

ID=89995281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU1998/000059 Ceased WO1998058655A1 (fr) 1997-06-24 1998-06-23 Utilisation medicale d'une substance contenant de l'acide humique

Country Status (3)

Country Link
AU (1) AU8236298A (fr)
HU (1) HUP9701093A1 (fr)
WO (1) WO1998058655A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024609A3 (fr) * 2000-09-19 2002-08-15 Nobel Ltd Liability Company Procede de production d'agents de protection contre les radiations
EP1369122A4 (fr) * 2001-02-21 2004-05-06 Nobel Ltd Liability Company Agent anticancereux

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016216A1 (fr) * 1991-03-16 1992-10-01 Torf Establishment Produits bioactifs derives de la tourbe, compositions pharmaceutiques et cosmetiques les contenant
WO1995008335A1 (fr) * 1993-09-24 1995-03-30 Maurizio Zanetti Traitement d'une infection hiv a l'aide d'acide humique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016216A1 (fr) * 1991-03-16 1992-10-01 Torf Establishment Produits bioactifs derives de la tourbe, compositions pharmaceutiques et cosmetiques les contenant
WO1995008335A1 (fr) * 1993-09-24 1995-03-30 Maurizio Zanetti Traitement d'une infection hiv a l'aide d'acide humique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; PUKHOVA G G ET AL: "[Effect of sodium humate on animals irradiated with lethal doses]. Vliianie gumata natriia na zhivotnykh, obluchennykh v letal'nykh dozakh.", XP002080637 *
INGLOT A D ET AL: "TOLPA TORF PREPARATION (TTP) INDUCES INTERFERON AND TUMOR NECROSIS FACTOR PRODUCTION IN HUMAN PERIPHERAL BLOOD LEUKOCYTES", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, vol. 41, no. 1, 1993, pages 73 - 80, XP000619722 *
RADIOBIOLOGIIA, (1987 SEP-OCT) 27 (5) 650-3 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024609A3 (fr) * 2000-09-19 2002-08-15 Nobel Ltd Liability Company Procede de production d'agents de protection contre les radiations
EP1369122A4 (fr) * 2001-02-21 2004-05-06 Nobel Ltd Liability Company Agent anticancereux
EP1810684A3 (fr) * 2001-02-21 2008-04-16 Nobel Limited Liability Company Agent anticancéreux

Also Published As

Publication number Publication date
HU9701093D0 (en) 1997-08-28
HUP9701093A1 (hu) 1999-08-30
AU8236298A (en) 1999-01-04

Similar Documents

Publication Publication Date Title
Goel et al. Humic substances: Prospects for use in agriculture and medicine
US4487766A (en) Growth stimulants and compositions containing same
KR101621335B1 (ko) 김 전용 영양제 및 그 제조 방법
CN112971151A (zh) 一种具有提高免疫力的人参核桃肽组合物及其制备方法
WO1998058655A1 (fr) Utilisation medicale d'une substance contenant de l'acide humique
CN1060782C (zh) 海藻多糖钙络合物及制备方法和用途
KR100922719B1 (ko) 미네랄 기능수의 제조방법, 이에 의해 제조된 미네랄 기능수
CN109956561A (zh) 一种水质净化剂及其制备方法
KR102135464B1 (ko) 활성 액상 미네랄의 제조방법
JP2013159593A (ja) 溶岩粉末及び火山灰を用いた生体内の有毒物質及び放射性物質の無毒化方法及び汚染された田畑の改善方法
CN104606261A (zh) 一种沸石药物组合物及其制备方法和用途
CN115590113B (zh) 一种天香菊饲料添加剂及其在对虾养殖中的应用
RU2405374C2 (ru) Кормовая добавка для сельскохозяйственной птицы и животных
CN112656937B (zh) 一种牛骨胶原蛋白肽组合物及其制备方法和应用
KR102135463B1 (ko) 활성 천연 미네랄을 포함하는 항생제 대체물질
KR20020016729A (ko) 유황과 광물질을 소재로한 오리 사료의 제조방법 및 그조성물
RU2220716C1 (ru) Способ получения микрокапсул, содержащих живые микроорганизмы
KR101946164B1 (ko) 유기게르마늄 및 유기셀레늄을 함유하는 유충의 사육방법
RU2707119C2 (ru) Способ коррекции биохимического статуса новорожденных телят
CN103638126B (zh) 一种防治鸭疫里默氏杆菌病的中药制剂及其制备方法
KR101800870B1 (ko) 가축의 면역 증강용 조성물 및 그 제조방법
RU2392827C1 (ru) Кормовая добавка для сельскохозяйственной птицы и животных
CN1063048C (zh) 水溶珍珠粉及其生产工艺
KR102699079B1 (ko) 비타민 a, d3, e를 함유한 나노제품 및 이를 이용한 동물용 영양제
RU2183124C1 (ru) Способ получения радиопротектора

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999504019

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase